Form 8-K - Current report:
SEC Accession No. 0000950170-25-008889
Filing Date
2025-01-24
Accepted
2025-01-24 17:14:05
Documents
12
Period of Report
2025-01-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-20250123.htm   iXBRL 8-K 46874
2 EX-10.1 virx-ex10_1.htm EX-10.1 129292
  Complete submission text file 0000950170-25-008889.txt   287098

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT virx-20250123.xsd EX-101.SCH 23863
15 EXTRACTED XBRL INSTANCE DOCUMENT virx-20250123_htm.xml XML 4543
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

EIN.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 25555112
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)